OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment. Its initial focus will be confirmatory diagnostics, utilizing liquid biopsy technology, for use in conjunction with imaging to confirm initial diagnoses within certain oncology indications. In addition, it will be developing screening diagnostics as replacements for screening imaging procedures. For some indications, it will also be pursuing the probability of recurrence of a specific cancer through the development of prognostics or companion diagnostics that help a physician determine which therapy is the optimal treatment for the patient. It offers diagnostic tests for lung, breast and bladder cancer.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Symbol: AMEX:OCX
- CUSIP: N/A
- Web: N/A
- 50 Day Moving Avg: $5.94
- 200 Day Moving Avg: $5.93
- 52 Week Range: $3.10 - $7.95
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -9.46
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.30 per share
- Price / Book: 17.67
- Average Volume: 42,160 shs.
- Short Ratio: 3.55
Frequently Asked Questions for OncoCyte Corp (AMEX:OCX)
What is OncoCyte Corp's stock symbol?
OncoCyte Corp trades on the AMEX under the ticker symbol "OCX."
Where is OncoCyte Corp's stock going? Where will OncoCyte Corp's stock price be in 2017?
3 equities research analysts have issued 1 year price targets for OncoCyte Corp's shares. Their forecasts range from $7.75 to $7.75. On average, they expect OncoCyte Corp's stock price to reach $7.75 in the next twelve months. View Analyst Ratings for OncoCyte Corp.
Who are some of OncoCyte Corp's key competitors?
Some companies that are related to OncoCyte Corp include Nantkwest (NK), Merus NV (MRUS), Minerva Neurosciences (NERV), Edge Therapeutics (EDGE), Sinovac Biotech (SVA), Entellus Medical (ENTL), Concert Pharmaceuticals (CNCE), RTI Surgical (RTIX), Rigel Pharmaceuticals (RIGL), Ignyta (RXDX), Novavax (NVAX), Dynavax Technologies (DVAX), XBiotech (XBIT), Veracyte (VCYT), Matinas BioPharma Holdings (MTNB), Nabriva Therapeutics AG - (NBRV), Tetraphase Pharmaceuticals (TTPH) and Senseonics Holdings (SENS).
How do I buy OncoCyte Corp stock?
Shares of OncoCyte Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of OncoCyte Corp stock cost?
One share of OncoCyte Corp stock can currently be purchased for approximately $5.30.
Earnings History for OncoCyte Corp (AMEX:OCX)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for OncoCyte Corp (AMEX:OCX)
2017 EPS Consensus Estimate: ($0.38)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for OncoCyte Corp (AMEX:OCX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for OncoCyte Corp (AMEX:OCX)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for OncoCyte Corp (AMEX:OCX)
Latest Headlines for OncoCyte Corp (AMEX:OCX)